Positive results from an ongoing phase II study of BIND-014 in non-small cell lung cancer showed that it has met the primary objective in the once-every-three-weeks arm, as measured by overall response rate. The data demonstrate that BIND-014 is well-tolerated with clinically meaningful anti-tumor activity at a lower dose than conventional docetaxel in patients with advanced or metastatic NSCLC.
A phase III trial of Tumor Treating Fields was terminated early following early success detailed in an interim analysis. The trial evaluated patients with newly diagnosed glioblastoma being treated with the NovoTTF-100A System, developed by Novocure, in combination with standard-of-care temozolomide.
Top-line secondary endpoint results from the phase III TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer did not demonstrate a statistically significant improvement in overall survival. The study evaluated trebananib plus paclitaxel versus placebo plus paclitaxel.
A study comparing Opdivo to dacarbazine chemotherapy in treatment naïve advanced melanoma patients marks first PD-1 immune checkpoint inhibitor to demonstrate a survival benefit in a phase III trial.
FDA approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Anamorelin, a once-daily ghrelin receptor agonist, significantly increased lean body mass compared to placebo in two phase III trials in non-small cell lung cancer patients with cachexia.
A final analysis of a phase III trial showed that Zytiga (abiraterone acetate) plus prednisone significantly prolonged overall survival compared to an active control of placebo plus prednisone, in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Results from the LUX-Head & Neck 1 study showed that afatinib significantly delayed tumor growth compared to chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20 percent.
A new analysis from the phase III SELECT trial of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer shows that the level of baseline angiopoietin-2 may be a predictive factor for lenvatinib response, tumor shrinkage and prolonged progression free survival. Angiopoietin-2 regulates the formation tumor blood vessels.
